This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sagher, D. Articles by Strauss, B. Search for Related Content PubMed PubMed Citation Articles by Sagher, D. Articles by Strauss, B.

Heterogeneity of O⁶-Alkylguanine-DNA Alkyltransferase Activity in Peripheral Blood Lymphocytes: Relationship between This Activity in Lymphocytes and in Lymphoblastoid Lines from Normal Controls and from Patients with Hodgkin's Disease or Non-Hodgkin's Lymphoma¹

Departments of Molecular Genetics and Cell Biology [D. S., B. S.], Medicine [T. K., R. A. L.], and Radiation and Cellular Oncology [J. L. S.], The University of Chicago, Illinois 60637

We determined O⁶-alkylguanine-DNA alkyltransferase (AGT) activity in the peripheral blood lymphocytes (PBLs) of normal controls and patients with Hodgkin's disease or non-Hodgkin's lymphoma and compared these values with those of Epstein-Barr virus (EBV)-transformed cell lines prepared from the same PBL samples. PBLs have an AGT level characteristic of the individual from whom the cells were obtained. The AGT activity of lymphoblastoid cell lines obtained from a control group of PBLs was significantly correlated with the activity of the PBLs from which they were derived (r = 0.742). There was no significant correlation between PBLs and EBV-transformed lines derived from these PBLs in Hodgkin's disease/non-Hodgkin's lymphoma patients (r = 0.407, -0.225, and 0.270 for patients prior to, during, or after therapy, respectively). The lack of significant correlation between lines and PBLs was not due to random fluctuations in AGT activity, because multiple lines prepared from the same PBL sample were found to be highly correlated in AGT activity. In order to account for these results, we suppose that PBLs from a given individual are a heterogeneous population with respect to AGT activity. In normal individuals, the AGT activity of early passages of the multi-clonal EBV-transformed cell lines reflect the AGT activity of the PBLs from which they were derived. Malignancy and/or treatment with chemotherapeutic agents may selectively affect those lymphocytes which are targets for EBV-transformation so that the resultant cell line is no longer representative (with respect to AGT activity) of the total PBL population. Long-term culture of lymphoblastoid cell lines results in changes in AGT activity in some but not all cell lines suggesting that with time in culture, subsets with different AGT activities may be selected. There appears to be no growth advantage of low AGT activity and only rarely have we obtained lines with no measurable AGT activity, even after long periods in culture.

¹ The investigations described in this paper were supported by Program Project Grant CA40046 from the National Cancer Institute.

² To whom requests for reprints should be addressed, at Department of Molecular Genetics & Cell Biology, 920 E. 58th Street, Chicago, IL 60637.

³ Recipient of a Junior Faculty Research Award from the American Cancer Society.

⁴ Recipient of a Clinical Oncology Career Development Award from the American Cancer Society.

Received 1/16/89. Revised 5/22/89. Accepted 7/ 5/89.

This article has been cited by other articles:

				G. P. Margison, A. C. Povey, B. Kaina, and M. F. Santibanez Koref Variability and regulation of O6-alkylguanine-DNA alkyltransferase Carcinogenesis, April 1, 2003; 24(4): 625 - 635. [Abstract] [Full Text] [PDF]

				B. J. Glassner, G. Weeda, J. M. Allan, J. L.M. Broekhof, N. H.E. Carls, I. Donker, B. P. Engelward, R. J. Hampson, R. Hersmus, M. J. Hickman, et al. DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents Mutagenesis, May 1, 1999; 14(3): 339 - 347. [Abstract] [Full Text] [PDF]

				A.L. Herrick, J.A. Rafferty, and G.P. Margison DNA repair deficiency in systemic lupus erythematosus: cause or consequence of disease and implications for management Lupus, December 1, 1995; 4(6): 423 - 424. [PDF]